How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

224 results for

Eslicarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Partial-onset seizures in epilepsy: perampanel as adjunctive treatment

) recommends carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate or topiramate as adjunctive treatment if monotherapy is ineffective or not tolerated. If adjunctive treatment is ineffective or not tolerated, the guideline recommends that advice should be sought from a tertiary epilepsy specialist. Anti-epileptic drugs that may be considered by the specialist at this point in the care pathway are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin (...) or not tolerated, advice should be sought from a tertiary epilepsy specialist. Anti-epileptic drugs that may be considered by the tertiary epilepsy specialist are eslicarbazepine acetate, lacosamide, phenobarbital, phenytoin, pregabalin, tiagabine, vigabatrin and zonisamide [1][3] Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 15The NICE

2012 National Institute for Health and Clinical Excellence - Advice

122. Perampanel (epilepsy and seizures) ? Benefit assessment according to §35a Social Code Book V

and older in comparison with the appropriate comparator therapy (ACT). The G-BA specified the following ACT: ? an individual antiepileptic add-on therapy, if medically indicated and if no pharmacoresistance/intolerance and contraindications are known yet, with one of the following drugs: eslicarbazepine (for adults) or gabapentin or lacosamide (for patients aged 16 years and older) or lamotrigine or levetiracetam or oxcarbazepine or pregabalin (for adults) or topiramate or valproic acid or zonisamide (...) Appropriate comparator therapy Extent and probability of added benefit As add-on therapy of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older An individual antiepileptic add-on therapy, if medically indicated and if no pharmacoresistance/intolerance and contraindications are known yet, with one of the following drugs: eslicarbazepine a or gabapentin or lacosamide b or lamotrigine or levetiracetam or oxcarbazepine or pregabalin

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

123. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. (Abstract)

Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. We have previously shown that cannabidiol (CBD; Epidiolex®) significantly affects levels of clobazam/N-desmethylclobazam, rufinamide, topiramate, zonisamide, and eslicarbazepine. In the present study, we tested whether the presence of concomitant clobazam affected seizure frequency and severity (treatment response) 12 weeks after initiation of therapy with CBD

2019 Epilepsy & behavior : E&B Controlled trial quality: uncertain

124. Use of Newer Anticonvulsants for the Treatment of Status Epilepticus. (Abstract)

status epilepticus (SRSE). The PubMed database was searched for clinical trials published between January 2000 and July 2018 using the search terms status epilepticus, refractory status epilepticus, super refractory status epilepticus, brivaracetam, clobazam, cannabidiol, eslicarbazepine, lacosamide, perampanel, rufinamide, stiripentol, and zonisamide. Trials that evaluated these agents in adults with SE, RSE, and SRSE were included. Brivaracetam use was identified in two retrospective reviews (...) with success rates of 27% and 57%. One unsuccessful case report of cannabidiol use in SE was found. Four clobazam studies were identified in SE and RSE with success rates ranging from 25-100%. No evidence for the use of eslicarbazepine and zonisamide was found. Using the search terms for lacosamide identified 38 articles: 1 systematic review, 5 prospective studies, 15 retrospective reviews, and 17 case reports. Success rates and dosing varied, but studies that included focal or partial types of SE showed

2019 Pharmacotherapy

126. Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use)

, Eslicarbazepine Acetate, Ethosuximide, Felbamate, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Lorazepam, Oxcarbazepine, Perampanel, Phenobarbital, Phenytoin, Pregabalin, Rufinamide, Valproic Acid, Vigabatrin, Zonisamide. Documentation must include the diagnosis of epilepsy type or epilepsy syndrome (if possible), as well as the underlying case, when known. Between 1-3 baseline anti-epileptic drugs at stable doses for a minimum of 4 weeks prior to enrollment. Vagus nerve stimulator, and dietary

2018 Clinical Trials

127. Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs. Full Text available with Trip Pro

-7-nitroquinoxaline-2,3-dione, (2R)-amino-5-phosphonovaleric acid, tetrodotoxin, or ASDs were bath applied for 20 minutes. Concentration-dependent effects and half maximal effective concentration values were determined for RED duration, frequency, and amplitude.ASDs targeting sodium and potassium channels (carbamazepine, eslicarbazepine, ezogabine, lamotrigine, lacosamide, phenytoin, and rufinamide) attenuated REDs at concentrations near their average therapeutic plasma concentrations. γ

2018 Epilepsia

128. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines Full Text available with Trip Pro

databases.Reference ranges varied between laboratories for four of 23 available AEDs (lamotrigine, valproate, eslicarbazepine and oxcarbazepine). For four AEDs (brivaracetam, perampanel, stiripentol and sulthiame), reference ranges had not previously been established. In total, 13 reference ranges were either harmonized, updated or newly established. No changes were applied to the remaining 10 AEDs.Updated and harmonized reference ranges are now available for 22 of the 23 AEDs available in Norway. The exception

2018 Drug design, development and therapy

130. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing

, eslicarbazepine acetate, and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele, and thus caution should be used in choosing alternatives to phenytoin (see Supplementary Material online for details). d Recommended maintenance dose based on patient’s clinical characteristics. 544 VOLUME 96 NUMBER 5 | NOVEMBER 2014 | www.nature.com/cptCPIC GuIdelInes HLA-B*15:02 with phenytoin-induced SJS/TEN (P < 3? ×? 10 –4 ; odds ratio = 4.26; 95% confidence interval (CI) = 1.93–9.39) under a fixed (...) carbamazepine and phenytoin, unless the benefits of treating the underlying disease clearly outweigh the risks (see Table 2). Some evidence exists linking SJS/TEN with the HLA-B*15:02 allele in association with the use of alternative medications such as oxcarbazepine, eslicarbazepine acetate, and lamotrigine, and thus caution should be used in choos- ing alternatives to phenytoin (see Supplementary Material online for details). CYP2C9 recommendations. Phenytoin and fosphenytoin dose should first be adjusted

2014 Clinical Pharmacogenetics Implementation Consortium

131. Antiepileptic drugs: new advice on switching between different manufacturers? products for a particular drug

For these drugs, doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product Category 2 – valproate, lamotrigine, perampanel, retigabine, rufinamide, clobazam, clonazepam, oxcarbazepine, eslicarbazepine, zonisamide, topiramate For these drugs, the need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

2013 MHRA Drug Safety Update

132. Interactions between cannabidiol and commonly used antiepileptic drugs. Full Text available with Trip Pro

to determine if the frequency of sedation in participants was related to the mean serum N-desmethylclobazam level, and if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were different in participants taking concomitant valproate.Increases in topiramate, rufinamide, and N-desmethylclobazam and decrease in clobazam (all p < 0.01) serum levels were seen with increasing CBD dose. Increases in serum levels of zonisamide (p = 0.02) and eslicarbazepine (p = 0.04) with increasing CBD (...) dose were seen in adults. Except for clobazam and desmethylclobazam, all noted mean level changes were within the accepted therapeutic range. Sedation was more frequent with higher N-desmethylclobazam levels in adults (p = 0.02), and AST/ALT levels were significantly higher in participants taking concomitant valproate (p < 0.01).Significantly changed serum levels of clobazam, rufinamide, topiramate, zonisamide, and eslicarbazepine were seen. Abnormal liver function test results were noted

2017 Epilepsia

133. The Risk of Specific Congenital Anomalies in Relation to Newer Antiepileptic Drugs: A Literature Review Full Text available with Trip Pro

The Risk of Specific Congenital Anomalies in Relation to Newer Antiepileptic Drugs: A Literature Review More information is needed about possible associations between the newer anti-epileptic drugs (AEDs) in the first trimester of pregnancy and specific congenital anomalies of the fetus.We performed a literature review to find signals for potential associations between newer AEDs (lamotrigine, topiramate, levetiracetam, gabapentin, oxcarbazepine, eslicarbazepine, felbamate, lacosamide

2016 Drugs - real world outcomes

134. Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients Full Text available with Trip Pro

, lacosamide and eslicarbazepine, under real-life conditions by means of an assessment of routine clinical data of inpatients.Over 2.75 years data of all inpatients receiving one of the newer AEDs were documented. Occurring adverse drug reactions (ADRs) were classified according to the WHO-UMC Causality Assessment concerning their likely relationship to the prescribed AEDs. For each AED, the total number of patients without and with ADRs, assessed as at least possibly related to the particular drug

2016 Drugs - real world outcomes

135. New developments in the management of partial-onset epilepsy: role of brivaracetam Full Text available with Trip Pro

observational trials and registries. Among newer anticonvulsant drugs for partial-onset seizures (POSs), rufinamide, lacosamide, eslicarbazepine and perampanel are those new treatment options for which more substantial clinical evidence is currently available, both in adults and, to some extent, in children. Among the newest anticonvulsant drugs, brivaracetam, a high-affinity synaptic vesicle protein 2A ligand, reported to be 10- to 30-fold more potent than levetiracetam, is highly effective in a broad

2017 Drug design, development and therapy

136. Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs Full Text available with Trip Pro

), treatment with more than one AED, and treatment with a novel AED. The definition for "novel" was newly approved at the time of market entry since 2006 (last 10 years): eslicarbazepine (ESL), lacosamide (LCM), perampanel (PER), and retigabine (RTG). Methods: The analysis was based on a claims data set covering the years 2007 to 2014, provided by AOK PLUS, a German statutory health insurance. Two patient samples were defined: (1) prevalent patients suffering from FE (at least one in- or outpatient

2017 GMS German Medical Science

137. A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Posted : April 17, 2017 Last Update Posted : March 5, 2019 Sponsor: Sunovion Information provided by (Responsible Party): Sunovion Study Details Study Description Go to Brief Summary: A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures Condition or disease Intervention/treatment Phase Epilepsy With Partial On-set Seizures Drug: Eslicarbazepine acetate Drug: Eslicarbazepine Acetate Phase 4 Detailed Description: This is a 31-week (...) , multicenter, 2-arm, prospective, open-label, non-randomized, Phase 4 study of eslicarbazepine acetate (ESL) as adjunctive therapy in adult subjects with a diagnosis of epilepsy with POS. Two groups of ESL-naïve subjects will be evaluated. The groups are defined as follows: Arm 1 (ESL as first add-on): This group will include subjects who have been maintained on a regimen consisting of a stable dose of LEV or LTG for at least 1 month (28 days) prior to screening and who have not used any adjunctive

2017 Clinical Trials

138. ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

provided by (Responsible Party): Eisai Inc. ( Eisai GmbH ) Study Details Study Description Go to Brief Summary: This is a non interventional prospective study. Centers will enroll adult participants with partial onset seizures with or without secondary generalisation for whom the clinician has decided to initiate eslicarbazepine acetate (ESL) as an adjunctive therapy or monotherapy prior to the decision to take part in this study. Participants to be enrolled into the study will receive ESL either (...) Perspective: Prospective Official Title: An Open, Multicentric, Non-Interventional Observational Study Investigating Retention, Seizure Control and Tolerability in Epilepsy Patients With Partial Onset Seizures Receiving Eslicarbazepine Acetate (ESL) in Different Therapy Situations Actual Study Start Date : July 2015 Estimated Primary Completion Date : October 2018 Estimated Study Completion Date : October 2018 Resource links provided by the National Library of Medicine related topics: related topics

2017 Clinical Trials

139. A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

in age) taking the drug (elsicarbazepine acetate) Condition or disease Intervention/treatment Phase Epilepsy Drug: Eslicarbazepine acetate Phase 3 Detailed Description: This is a long-term, multicenter, open-label, safety, tolerability, and maintenance of effect study of flexible daily dosing with Eslicarbazepine acetate (ESL) in subjects 4 to 17 years of age with partial onset seizures (POS). The study is designed to enroll subjects to receive ESL as adjunctive treatment with the option to convert (...) information Study Type : Interventional (Clinical Trial) Actual Enrollment : 0 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Masking Description: Open label Primary Purpose: Treatment Official Title: An Open-label Eslicarbazepine Acetate Long-term Safety and Tolerability Study in Children and Adolescents (4 - 17 Years) Actual Study Start Date : July 6, 2017 Actual Primary Completion Date : October 26, 2017 Actual Study Completion Date : October 26, 2017 Resource links

2017 Clinical Trials

140. Central Pain Study for ABX-1431

episode within 60 days before the study start. Patients with unresolved infections, AIDS myelopathy, or degenerative neurological conditions. Patient has received the following within 60 days before study start: Intrathecal baclofen. Injection therapies such a botulinum toxin, anesthetic or nerve block to control pain. Plasma exchange Patients taking daily oral opioid drugs are excluded. Patient is taking carbamazepine or oxcarbazine or eslicarbazepine or other potent cytochrome P450 3A4/5 inducers

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>